Month: October 2025

Italy-based biotech company NanoPhoria Bioscience has announced the initial closing of its Series A funding round, raising €83.5m ($98m).

The round was led by XGEN Venture, Sofinnova Partners and CDP Venture Capital. Panakès Partners and an undisclosed investor also participated.

NanoPhoria will use the funds to advance the development of its lead candidate, NP-MP1, aimed at treating heart failure with reduced ejection fraction (HFrEF). The proceeds will be utilised for investigational new drug (IND)-enabling trials and early clinical development of NP-MP1.

Please click here to read more

• AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutation
• AAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue recruiting in our STELLA observational study

Please click here to read more